Zacks Research Issues Negative Forecast for AGIO Earnings

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Free Report) - Investment analysts at Zacks Research reduced their Q1 2025 earnings per share estimates for Agios Pharmaceuticals in a report released on Wednesday, December 11th. Zacks Research analyst A. Chakraborty now anticipates that the biopharmaceutical company will earn ($1.64) per share for the quarter, down from their prior estimate of ($1.63). The consensus estimate for Agios Pharmaceuticals' current full-year earnings is ($0.39) per share. Zacks Research also issued estimates for Agios Pharmaceuticals' Q4 2025 earnings at ($1.72) EPS, FY2025 earnings at ($6.77) EPS, Q1 2026 earnings at ($1.48) EPS, Q3 2026 earnings at ($1.41) EPS and FY2026 earnings at ($5.70) EPS.

AGIO has been the topic of several other research reports. StockNews.com upgraded Agios Pharmaceuticals from a "sell" rating to a "hold" rating in a research note on Saturday, November 9th. Royal Bank of Canada increased their price target on Agios Pharmaceuticals from $55.00 to $57.00 and gave the stock an "outperform" rating in a research report on Tuesday, December 10th. Leerink Partners cut Agios Pharmaceuticals from an "outperform" rating to a "market perform" rating and dropped their price target for the stock from $60.00 to $56.00 in a research report on Friday, September 27th. Leerink Partnrs cut Agios Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research report on Friday, September 27th. Finally, Scotiabank increased their price target on Agios Pharmaceuticals from $53.00 to $75.00 and gave the stock a "sector outperform" rating in a research report on Monday, December 9th. Five equities research analysts have rated the stock with a hold rating and four have given a buy rating to the stock. According to MarketBeat, the stock has an average rating of "Hold" and a consensus price target of $56.33.

Agios Pharmaceuticals Price Performance

AGIO traded up $3.72 on Monday, reaching $42.69. The company's stock had a trading volume of 1,451,998 shares, compared to its average volume of 720,508. The stock has a market cap of $2.43 billion, a price-to-earnings ratio of 3.76 and a beta of 0.80. Agios Pharmaceuticals has a 1 year low of $20.96 and a 1 year high of $62.58. The business's 50 day moving average is $50.06 and its 200 day moving average is $46.80.

Insider Activity at Agios Pharmaceuticals

In other Agios Pharmaceuticals news, CFO Cecilia Jones sold 2,542 shares of the stock in a transaction on Thursday, September 26th. The stock was sold at an average price of $49.03, for a total transaction of $124,634.26. Following the completion of the transaction, the chief financial officer now directly owns 20,158 shares of the company's stock, valued at approximately $988,346.74. This trade represents a 11.20 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 4.93% of the stock is owned by insiders.

Institutional Investors Weigh In On Agios Pharmaceuticals

Large investors have recently modified their holdings of the stock. Northcape Wealth Management LLC purchased a new stake in shares of Agios Pharmaceuticals in the second quarter valued at $244,000. Bank of New York Mellon Corp lifted its holdings in shares of Agios Pharmaceuticals by 13.9% in the second quarter. Bank of New York Mellon Corp now owns 223,151 shares of the biopharmaceutical company's stock valued at $9,622,000 after purchasing an additional 27,193 shares in the last quarter. Panagora Asset Management Inc. purchased a new stake in shares of Agios Pharmaceuticals in the second quarter valued at $7,540,000. TD Asset Management Inc raised its holdings in shares of Agios Pharmaceuticals by 34.6% during the second quarter. TD Asset Management Inc now owns 210,472 shares of the biopharmaceutical company's stock worth $9,076,000 after acquiring an additional 54,054 shares in the last quarter. Finally, North Star Asset Management Inc. purchased a new stake in shares of Agios Pharmaceuticals during the second quarter worth $216,000.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.